Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic cancer
Stage/Subtype:  brain metastases
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 61 for your search:
Start Over
Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: EF-25, NCI-2017-00033, NCT02831959
Whole-Brain Radiotherapy or Stereotactic Radiosurgery in Treating Patients with 5-15 Metastatic Malignant Tumors in the Brain
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 80
Trial IDs: 16-305, NCI-2017-00755, NCT03075072
Stereotactic Radiosurgery in Treating Patients with Large Brain Metastases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE8312, NCI-2013-00845, NCT01843413
Radiosurgery before Surgery in Treating Patients with Brain Metastases That Can Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7312, NCI-2013-00644, NCT01891318
A Trial of AP32788 in Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AP32788-15-101, NCI-2016-00587, NCT02716116
Nivolumab and Radiation Therapy with or without Ipilimumab in Treating Patients with Brain Metastases from Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0883, NCI-2016-00661, NCT02696993
Cyclodextrin-based polymer-camptothecin CRLX101 and Olaparib in Treating Patients with Relapsed or Refractory Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0107, NCI-2016-00748, P152527, NCT02769962
Trastuzumab Emtansine with or without Temozolomide in Preventing Development of Brain Metastases after Stereotactic Radiosurgery in Patients with HER2 Positive Brea t Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0115, NCI-2017-01113, NCT03190967
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG-1119, NCI-2012-01977, CDR0000735353, NCT01622868
Dabrafenib and Stereotactic Radiosurgery in Treating Patients With Melanoma and Brain Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC # 12857, NCI-2012-02214, NCT01721603
Dacomitinib in Treating Patients with Progressive Brain Metastases
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCSD 130418, NCI-2014-00818, 130418, DP01-WS2043189, NCT02047747
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients with Stage II-IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-252, NCI-2014-00216, NCT02073968
Pembrolizumab in Treating Patients with Metastatic Melanoma or Non-small Cell Lung Cancer and Untreated Brain Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 1401013290, NCI-2015-02019, PN027, NCT02085070
Cabozantinib-s-malate in Treating Patients with Previously Treated Non-small Cell Lung Cancer and Brain Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-182, NCI-2014-01505, PRO14050009, UPCI #13-182, NCT02132598
Cabozantinib S-malate with or without Trastuzumab in Treating Patients with Breast Cancer and Brain Metastases
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-359, NCI-2014-02365, NCT02260531
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15450, NCI-2015-00514, 2014-004010-28, I3Y-MC-JPBO, NCT02308020
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, 350, 351, NCT02312622
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLDK378A2205, NCI-2015-00957, NCT02336451
Eribulin Mesylate in Treating Patients with Brain Metastases from Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7113, NCI-2015-01792, NCT02581839
Durvalumab in Treating Patients with Solid Tumors that Has Metastasized to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201602169, NCI-2016-00411, NCT02669914
Start Over